ANTEOTECH LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.023 AUD | 0.00% |
|
+4.55% | -36.11% |
| Sales 2022 | 761K 495K | Sales 2023 | 366K 238K | Capitalization | 82M 53.36M |
|---|---|---|---|---|---|
| Net income 2022 | -10M -6.51M | Net income 2023 | -12M -7.81M | EV / Sales 2022 | 158 x |
| Net cash position 2022 | 9.07M 5.9M | Net cash position 2023 | 1.41M 920K | EV / Sales 2023 | 220 x |
| P/E ratio 2022 |
-12
x | P/E ratio 2023 |
-6.33
x | Employees | 99 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.47% |
More Fundamentals
* Assessed data
More news
| 1 week | +4.55% | ||
| Current month | -37.84% | ||
| 1 month | -37.84% | ||
| 3 months | -34.29% | ||
| 6 months | -20.69% | ||
| Current year | -36.11% |
1 week
0.02
0.02
1 month
0.020.04
Current year
0.020.04
1 year
0.020.06
3 years
0.020.50
5 years
0.010.50
10 years
0.010.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 08-12-31 | |
David Radford
CEO | Chief Executive Officer | - | 22-10-03 |
Andrew Cook
DFI | Director of Finance/CFO | - | 23-08-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 21-08-31 | |
| Director/Board Member | - | 21-08-31 | |
David Radford
CEO | Chief Executive Officer | - | 22-10-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.023 | 0.00% | 99,301 |
| 24-04-23 | 0.023 | 0.00% | 459,136 |
| 24-04-22 | 0.023 | 0.00% | 1,479,909 |
| 24-04-19 | 0.023 | +4.55% | 451,158 |
| 24-04-18 | 0.022 | 0.00% | 5,556,805 |
Delayed Quote Australian S.E., April 23, 2024 at 11:18 pm EDT
More quotes
AnteoTech Limited is an Australia-based surface chemistry company. The principal activities of the Company consist of research, development and commercialization of technologies with surface management applications. The activities are primarily focused on the commercialization of these technologies across applications in the Life Science and Clean Energy Technology markets. Its lead product, AnteoX, provides significant improvement in anode performance and the Company has partnered with global suppliers in lithium-ion battery manufacturing. The life sciences division services the point of care and diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy. It also offers bioconjugation and assay development services to assist point of care and diagnostics researchers and manufacturers in product development. It also offers ready-to-use kits.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.11% | 35.94M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- ADO Stock
